Timothy P. Noyes - Mar 1, 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Mar 1, 2023
Transactions value $
-$325,096
Form type
4
Date filed
3/3/2023, 05:00 PM
Previous filing
Feb 3, 2023
Next filing
Mar 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $32.1K +15K $2.14* 15K Mar 1, 2023 Direct F1
transaction AVTE Common Stock Sale -$135K -5.96K -39.75% $22.71 9.04K Mar 1, 2023 Direct F1, F2
transaction AVTE Common Stock Sale -$63.6K -2.67K -29.56% $23.81 6.37K Mar 1, 2023 Direct F1, F3
transaction AVTE Common Stock Sale -$131K -5.32K -83.51% $24.69 1.05K Mar 1, 2023 Direct F1, F4
transaction AVTE Common Stock Sale -$27K -1.05K -100% $25.67 0 Mar 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -15K -3.35% $0.00 433K Mar 1, 2023 Common Stock 15K $2.14 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.25 to $23.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.31 to $24.20, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.33 to $25.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.